NO20050543L - Antigene sammensetninger - Google Patents

Antigene sammensetninger

Info

Publication number
NO20050543L
NO20050543L NO20050543A NO20050543A NO20050543L NO 20050543 L NO20050543 L NO 20050543L NO 20050543 A NO20050543 A NO 20050543A NO 20050543 A NO20050543 A NO 20050543A NO 20050543 L NO20050543 L NO 20050543L
Authority
NO
Norway
Prior art keywords
antigenic compositions
carbohydrate
antigen
sublimation
administration
Prior art date
Application number
NO20050543A
Other languages
English (en)
Inventor
Vincent Vande Velde
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20050543L publication Critical patent/NO20050543L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives nye antigene sammensetninger egnet for parenteral og mukosal administrering, som omfatter et antigen i et vandig medium og et karbohydrat, hvor karbohydratet er i form av et derivat som oppviser sure deler, fortrinnsvis i form av dets karboksylsyrederivat. De antigene sammensetningene er i en stabil fast form og som etter rekonstituering med et flytende hjelpestoff eller adjuvans, etter administrering parenteralt eller mukosalt, hurtig løses i kroppsvæskene, for derved åfrigjøre den rekonstituerte vaksine i kroppen. Nærmere bestemt kan den lyofiliserte form bestå av et pulver eller en kake inneholdende antigenet, fortrinnsvis i en amorf (giassaktig) tilstand, som dannes av en flytende løsning eller suspensjon ved tørking eller sublimasjon, fortrinnsvis sublimasjon ved lyofilisering.
NO20050543A 2002-08-13 2005-01-31 Antigene sammensetninger NO20050543L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218821.7A GB0218821D0 (en) 2002-08-13 2002-08-13 Novel compositions
PCT/EP2003/009010 WO2004016241A1 (en) 2002-08-13 2003-08-12 Antigenic compositions

Publications (1)

Publication Number Publication Date
NO20050543L true NO20050543L (no) 2005-03-11

Family

ID=9942239

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050543A NO20050543L (no) 2002-08-13 2005-01-31 Antigene sammensetninger

Country Status (19)

Country Link
US (1) US20060051372A1 (no)
EP (1) EP1528914B1 (no)
JP (1) JP2006500358A (no)
KR (1) KR20050056965A (no)
CN (1) CN1674867A (no)
AT (1) ATE409459T1 (no)
AU (1) AU2003255440A1 (no)
BR (1) BR0313337A (no)
CA (1) CA2494002A1 (no)
DE (1) DE60323842D1 (no)
GB (1) GB0218821D0 (no)
IL (1) IL166526A0 (no)
IS (1) IS7671A (no)
MX (1) MXPA05001728A (no)
NO (1) NO20050543L (no)
PL (1) PL375590A1 (no)
RU (1) RU2005102589A (no)
WO (1) WO2004016241A1 (no)
ZA (1) ZA200500833B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
EP2272502A1 (en) * 2003-12-19 2011-01-12 Alk-Abelló A/S Cryogranules of a liquid composition of an allergen product
US20080145383A1 (en) * 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
JP2008096503A (ja) * 2006-10-06 2008-04-24 Toshiba Corp 粉末状感光性組成物の製造方法、感光性組成物およびこの感光性組成物から形成された光記録媒体
EP2148697B1 (en) * 2007-05-24 2012-10-03 GlaxoSmithKline Biologicals S.A. Lyophilised cpg containing wt-1 composition
EP2200642B1 (en) * 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
US20160317646A1 (en) * 2013-12-19 2016-11-03 Crucell Holland B.V. Formulations for virosomes
WO2016138362A1 (en) * 2015-02-26 2016-09-01 The Board Of Trustees Of The University Of Arkansas Treatment vaccine for prostate cancer
KR20190057345A (ko) * 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
BR112021000529A2 (pt) * 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarídeos secos
CN117100707A (zh) * 2023-10-19 2023-11-24 江苏瑞科生物技术股份有限公司 一种针对hpv免疫原性蛋白的冻干保护剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186908A (en) * 1962-08-16 1965-06-01 Parke Davis & Co Calcium lactobionate stabilization of labile antigenic virus vaccine materials
DE3585835D1 (de) * 1984-12-07 1992-05-14 Faruk Hadziselimovic Praeparat zur intramuskulaeren injektion von medikamenten, vitaminen oder impfstoffen.
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
NZ505324A (en) * 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration

Also Published As

Publication number Publication date
MXPA05001728A (es) 2005-05-27
PL375590A1 (en) 2005-11-28
CN1674867A (zh) 2005-09-28
KR20050056965A (ko) 2005-06-16
BR0313337A (pt) 2005-06-14
EP1528914A1 (en) 2005-05-11
IS7671A (is) 2005-01-27
AU2003255440A1 (en) 2004-03-03
JP2006500358A (ja) 2006-01-05
CA2494002A1 (en) 2004-02-26
WO2004016241A1 (en) 2004-02-26
GB0218821D0 (en) 2002-09-18
ZA200500833B (en) 2006-08-30
ATE409459T1 (de) 2008-10-15
IL166526A0 (en) 2006-01-15
DE60323842D1 (de) 2008-11-13
EP1528914B1 (en) 2008-10-01
RU2005102589A (ru) 2005-10-10
US20060051372A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20050543L (no) Antigene sammensetninger
EP1858487B1 (en) Chemically defined stabiliser composition
Rexroad et al. Lyophilization and the thermostability of vaccines
Burke et al. Formulation, stability, and delivery of live attenuated vaccines for human use
EP1187907B1 (en) Method for the preservation of biologically-active material
US8273374B2 (en) Preservation of bioactive materials by spray drying
Amorij et al. Development of stable influenza vaccine powder formulations: challenges and possibilities
TWI670085B (zh) 液體穩定之豬病毒疫苗
US20110243988A1 (en) Methods and Compositions for Stabilization of a Virus Vaccine
JP2006503830A (ja) ワクチンの改良
HUP0303278A2 (hu) Fagyasztva szárított pantoprazol készítmény, eljárás az előállítására és pantoprazol injekció
EP2822540B1 (en) Methods and compositions for stabilizing dried biological materials
US6664099B1 (en) Method for the preservation of viruses and mycoplasma
CN102892409B (zh) 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法
KR20100028561A (ko) 냉동 건조 발포체에 의한 생활성 물질의 보존
JP2011514337A (ja) 糖ガラス化ウィルス様粒子（ｖｌｐ）
EP3057612B1 (en) Method of obtaining thermostable dried vaccine formulations
US10369213B2 (en) Thermostable respiratory synctial virus (RSV) vaccine compositions
WO2012028315A1 (en) A stabilizer for the preparation of a dry polio injectable vaccine composition
JP6494232B2 (ja) 粘膜ワクチン組成物
Lv et al. Preparation and heat resistance study of porcine reproductive and respiratory syndrome virus sugar glass vaccine
JPH0662433B2 (ja) ヘモフイルス・パラガリナ−ラムの粉状ワクチン製造法
JPH0688910B2 (ja) ヘモフイルス・プルロニユ−モニエの粉状ワクチン製造法
RU2003124491A (ru) Вакцина ассоциированная против сальмонеллеза и колибактериоза нутрий

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application